Identification, synthesis and structure assignment of two impurities of Erlotinib, a drug used for the treatment of some types of cancer.

  • María Guadalupe Morales-Vilchis Signa S.A de C.V.
  • Patricia Flores-Sánchez Signa S.A. de C.V.
  • Jaime Escalante Centro de Investigaciones Químicas de la Universidad Autónoma del Estado de Morelos http://orcid.org/0000-0001-5485-0244
Keywords: Eritronib, Cancer, Isomers, Impurity

Abstract

In the synthesis and industrial production of Erlotinib, the formation of organic impurities has been detected, so the identification and control of these is a critical point within the process. Standards for the consumption of pharmaceutical products are well established for active substances. In this sense, the synthesis and unequivocal identification of two impurities of Erlotinib as structural isomers was developed in the present study. The structural characterization of both isomers was confirmed by 1H and 13C-NMR as well as by their X-ray diffraction study.

References

Harris, C.; Hennequin, L.; Willerval, O. Tetrahedron Lett.2009, 50, 1600-1602.

Chandregowda, V.; Rao, V. G.; Reddy, G. C. Org. Process Res. Dev. 2007, 11, 813-816.

Zhang, G.; Zha, L. Res. Chem. Intermed. 2013, 39, 2303–2309.

Bridjes, A. J. Chem. Rev. 2001, 101, 2541-2572.

Bagul, C.; Rao, G. K.; Makani, V. K. K.; Tamboli, J. R.; Pal-Bhadra, M.; Kamal, A. Med. Chem. Commun. 2017, 8, 1810-1816.

Schnur, R. C.; Arnold, L. D. from PCT Int. Appl. (1996), WO 9639347 A1 Oct 03, 1996.

Q3A(R2) Impurities in New Drug Substances, ICH Tripartite Guideline.

Volk, B.; Dancsó, A.; Bakó, T.; Peltz, C.; Simig, G. Org. Process Res. Dev. 2011, 15, 339-342.

Crystallographic data was deposited at Cambridge Crystallographic Data Center (CCDC 1535571 for 4 and 1535572 for 5).

Crossland, R. K.; Servis, K. L. J. Org. Chem. 1970, 35, 3195-3196.

Published
04-24-2019